Chia-Chen Liu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1054586/publications.pdf Version: 2024-02-01



CHIA-CHEN LUL

#	Article	IF	CITATIONS
1	ApoE4 reduction: An emerging and promising therapeutic strategy for Alzheimer's disease. Neurobiology of Aging, 2022, 115, 20-28.	1.5	20
2	Clinicopathologic Factors Associated With Reversion to Normal Cognition in Patients With Mild Cognitive Impairment. Neurology, 2022, 98, .	1.5	7
3	ApoE Cascade Hypothesis in the pathogenesis of Alzheimer's disease and related dementias. Neuron, 2022, 110, 1304-1317.	3.8	120
4	TREM2 interacts with TDP-43 and mediates microglial neuroprotection against TDP-43-related neurodegeneration. Nature Neuroscience, 2022, 25, 26-38.	7.1	52
5	Mitophagy alterations in Alzheimer's disease are associated with granulovacuolar degeneration and early tau pathology. Alzheimer's and Dementia, 2021, 17, 417-430.	0.4	34
6	Vascular ApoE4 Impairs Behavior by Modulating Gliovascular Function. Neuron, 2021, 109, 438-447.e6.	3.8	42
7	Generation and validation of APOE knockout human iPSC-derived cerebral organoids. STAR Protocols, 2021, 2, 100571.	0.5	4
8	Apolipoprotein E regulates lipid metabolism and α-synuclein pathology in human iPSC-derived cerebral organoids. Acta Neuropathologica, 2021, 142, 807-825.	3.9	25
9	<i>APOE3</i> -Jacksonville (V236E) variant reduces self-aggregation and risk of dementia. Science Translational Medicine, 2021, 13, eabc9375.	5.8	37
10	Preparation of single cell suspensions enriched in mouse brain vascular cells for single-cell RNA sequencing. STAR Protocols, 2021, 2, 100715.	0.5	2
11	Astrocyte-derived clusterin suppresses amyloid formation in vivo. Molecular Neurodegeneration, 2020, 15, 71.	4.4	26
12	Activation of FAK/Rac1/Cdc42â€GTPase signaling ameliorates impaired microglial migration response to Aβ ₄₂ in triggering receptor expressed on myeloid cells 2 lossâ€ofâ€function murine models. FASEB Journal, 2020, 34, 10984-10997.	0.2	24
13	APOE4 exacerbates synapse loss and neurodegeneration in Alzheimer's disease patient iPSC-derived cerebral organoids. Nature Communications, 2020, 11, 5540.	5.8	172
14	Tau and apolipoprotein E modulate cerebrovascular tight junction integrity independent of cerebral amyloid angiopathy in Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, 1372-1383.	0.4	34
15	Alzheimer's Risk Factors Age, APOE Genotype, and Sex Drive Distinct Molecular Pathways. Neuron, 2020, 106, 727-742.e6.	3.8	152
16	APOE4 exacerbates $\hat{l}\pm$ -synuclein pathology and related toxicity independent of amyloid. Science Translational Medicine, 2020, 12, .	5.8	90
17	Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. Nature Reviews Neurology, 2019, 15, 501-518.	4.9	734
18	Soluble TREM2 ameliorates pathological phenotypes by modulating microglial functions in an Alzheimer's disease model. Nature Communications, 2019, 10, 1365.	5.8	217

CHIA-CHEN LIU

#	Article	IF	CITATIONS
19	5-HT3 Antagonist Ondansetron Increases apoE Secretion by Modulating the LXR-ABCA1 Pathway. International Journal of Molecular Sciences, 2019, 20, 1488.	1.8	14
20	APOE4-mediated amyloid-β pathology depends on its neuronal receptor LRP1. Journal of Clinical Investigation, 2019, 129, 1272-1277.	3.9	96
21	Apolipoprotein E, Receptors, and Modulation of Alzheimer's Disease. Biological Psychiatry, 2018, 83, 347-357.	0.7	265
22	Behavioral and transcriptomic analysis of Trem2-null mice: not all knockout mice are created equal. Human Molecular Genetics, 2018, 27, 211-223.	1.4	50
23	Pericyte implantation in the brain enhances cerebral blood flow and reduces amyloid-β pathology in amyloid model mice. Experimental Neurology, 2018, 300, 13-21.	2.0	53
24	Amyloid, tau, pathogen infection and antimicrobial protection in Alzheimer's disease –conformist, nonconformist, and realistic prospects for AD pathogenesis. Translational Neurodegeneration, 2018, 7, 34.	3.6	77
25	APOE ε2 is associated with increased tau pathology in primary tauopathy. Nature Communications, 2018, 9, 4388.	5.8	100
26	TREM2 Promotes Microglial Survival by Activating Wnt/β-Catenin Pathway. Journal of Neuroscience, 2017, 37, 1772-1784.	1.7	242
27	Soluble TREM2 induces inflammatory responses and enhances microglial survival. Journal of Experimental Medicine, 2017, 214, 597-607.	4.2	258
28	Astrocytic LRP1 Mediates Brain AÎ ² Clearance and Impacts Amyloid Deposition. Journal of Neuroscience, 2017, 37, 4023-4031.	1.7	175
29	Subacute ibuprofen treatment rescues the synaptic and cognitive deficits in advanced-aged mice. Neurobiology of Aging, 2017, 53, 112-121.	1.5	26
30	Apolipoprotein E4 Impairs Neuronal Insulin Signaling by Trapping Insulin Receptor in the Endosomes. Neuron, 2017, 96, 115-129.e5.	3.8	217
31	ApoE4 Accelerates Early Seeding of Amyloid Pathology. Neuron, 2017, 96, 1024-1032.e3.	3.8	258
32	Loss of clusterin shifts amyloid deposition to the cerebrovasculature via disruption of perivascular drainage pathways. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E6962-E6971.	3.3	96
33	ldentification of plexin A4 as a novel clusterin receptor links two Alzheimer's disease risk genes. Human Molecular Genetics, 2016, 25, 3467-3475.	1.4	21
34	LRP1 modulates the microglial immune response via regulation of JNK and NF-κB signaling pathways. Journal of Neuroinflammation, 2016, 13, 304.	3.1	101
35	ABCA7 Deficiency Accelerates Amyloid-β Generation and Alzheimer's Neuronal Pathology. Journal of Neuroscience, 2016, 36, 3848-3859.	1.7	109
36	Impact of sex and APOE4 on cerebral amyloid angiopathy in Alzheimer's disease. Acta Neuropathologica, 2016, 132, 225-234.	3.9	73

CHIA-CHEN LIU

#	Article	IF	CITATIONS
37	Quercetin stabilizes apolipoprotein E and reduces brain AÎ ² levels in amyloid model mice. Neuropharmacology, 2016, 108, 179-192.	2.0	52
38	Neuronal heparan sulfates promote amyloid pathology by modulating brain amyloid-β clearance and aggregation in Alzheimer's disease. Science Translational Medicine, 2016, 8, 332ra44.	5.8	115
39	Apolipoprotein E lipoprotein particles inhibit amyloid-β uptake through cell surface heparan sulphate proteoglycan. Molecular Neurodegeneration, 2016, 11, 37.	4.4	45
40	Rescuing effects of RXR agonist bexarotene on aging-related synapse loss depend on neuronal LRP1. Experimental Neurology, 2016, 277, 1-9.	2.0	50
41	Opposing roles of the triggering receptor expressed on myeloid cells 2 and triggering receptor expressed on myeloid cells-like transcript 2 in microglia activation. Neurobiology of Aging, 2016, 42, 132-141.	1.5	89
42	Vascular Cell Senescence Contributes to Blood–Brain Barrier Breakdown. Stroke, 2016, 47, 1068-1077.	1.0	167
43	Frontotemporal dementia-associated N279K tau mutant disrupts subcellular vesicle trafficking and induces cellular stress in iPSC-derived neural stem cells. Molecular Neurodegeneration, 2015, 10, 46.	4.4	58
44	Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and Al² metabolism in apoE4-targeted replacement mice. Molecular Neurodegeneration, 2015, 10, 6.	4.4	114
45	TREM2 in CNS homeostasis and neurodegenerative disease. Molecular Neurodegeneration, 2015, 10, 43.	4.4	115
46	Neuronal LRP1 Regulates Clucose Metabolism and Insulin Signaling in the Brain. Journal of Neuroscience, 2015, 35, 5851-5859.	1.7	110
47	Decreased platelet 5-hydroxytryptamin (5-HT) levels: a response to antidepressants. Journal of Affective Disorders, 2015, 187, 84-90.	2.0	27
48	Apolipoprotein E Is a Ligand for Triggering Receptor Expressed on Myeloid Cells 2 (TREM2). Journal of Biological Chemistry, 2015, 290, 26043-26050.	1.6	395
49	Tyrosine-based Signal Mediates LRP6 Receptor Endocytosis and Desensitization of Wnt/β-Catenin Pathway Signaling. Journal of Biological Chemistry, 2014, 289, 27562-27570.	1.6	33
50	Retinoic Acid Isomers Facilitate Apolipoprotein E Production and Lipidation in Astrocytes through the Retinoid X Receptor/Retinoic Acid Receptor Pathway. Journal of Biological Chemistry, 2014, 289, 11282-11292.	1.6	62
51	Deficiency in LRP6-Mediated Wnt Signaling Contributes to Synaptic Abnormalities and Amyloid Pathology in Alzheimer's Disease. Neuron, 2014, 84, 63-77.	3.8	168
52	Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nature Reviews Neurology, 2013, 9, 106-118.	4.9	2,482